Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C18H20FN3O4.H2O |
Molecular Weight | 740.7503 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4.C[C@H]5COC6=C7N5C=C(C(O)=O)C(=O)C7=CC(F)=C6N8CCN(C)CC8
InChI
InChIKey=SUIQUYDRLGGZOL-RCWTXCDDSA-N
InChI=1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C18H20FN3O4 |
Molecular Weight | 361.3675 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14506016
Curator's Comment: levofloxacin penetrates the cerebrospinal fluid (CSF) during meningeal inflammation both in animals and in humans
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363033 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26525786 |
|||
Target ID: CHEMBL2311225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26459538 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
|||
Curative | LEVAQUIN Approved UseLEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Launch Date8.5104001E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.9 mg/L |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.8 mg/L |
500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
11.8 mg/L |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.85 mg/L |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
2.04 mg/L |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.3 mg/L |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
49.6 mg × h/L |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
59 mg × h/L |
500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
118 mg × h/L |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
111 mg × h/L |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
19.88 mg × h/L |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
55.3 mg × h/L |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.6 h |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.4 h |
500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
8.9 h |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.9 h |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
5.97 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.6 h |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
LEVOFLOXACIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Sources: Page: 19Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.4%) Sources: Page: 19Nausea (0.6%) Vomiting (0.4%) Dizziness (0.3%) Headache (0.2%) |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Disc. AE: Gastrointestinal disorder, Nausea... AEs leading to discontinuation/dose reduction: Gastrointestinal disorder (1.2%) Sources: Page: 19Nausea (0.6%) Vomiting (0.5%) Dizziness (0.3%) Headache (0.3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | 0.2% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Dizziness | 0.3% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Vomiting | 0.4% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Nausea | 0.6% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Gastrointestinal disorder | 1.4% Disc. AE |
250 mg 1 times / day multiple, oral Recommended Dose: 250 mg, 1 times / day Route: oral Route: multiple Dose: 250 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Headache | 0.2% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Dizziness | 0.3% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Vomiting | 0.4% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Nausea | 0.6% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Gastrointestinal disorder | 1.4% Disc. AE |
500 mg 1 times / day steady, oral Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Dizziness | 0.3% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Headache | 0.3% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Vomiting | 0.5% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Nausea | 0.6% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Gastrointestinal disorder | 1.2% Disc. AE |
750 mg 1 times / day steady, oral Recommended Dose: 750 mg, 1 times / day Route: oral Route: steady Dose: 750 mg, 1 times / day Sources: Page: 19 |
unhealthy, mean 50 years n = 7537 Health Status: unhealthy Condition: infectious diseases Age Group: mean 50 years Sex: M+F Population Size: 7537 Sources: Page: 19 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
inconclusive | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/19026171/ Page: - |
yes [IC50 210 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/16928358/ Page: - |
yes [IC50 6800 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/27853934/ Page: - |
yes |
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/16474415/ Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Levofloxacin. | 1999 Nov |
|
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. | 2000 Sep |
|
In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci. | 2001 |
|
The role of fluoroquinolones in tuberculosis today. | 2001 |
|
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. | 2001 Apr |
|
Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99). | 2001 Apr |
|
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria]. | 2001 Apr |
|
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion. | 2001 Apr |
|
Which fluoroquinolones are suitable for the treatment of urinary tract infections? | 2001 Apr |
|
In vivo synergy between green tea extract and levofloxacin against enterohemorrhagic Escherichia coli O157 infection. | 2001 Apr |
|
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. | 2001 Aug 15 |
|
Quinolones alter defense reactions mediated by macrophages. | 2001 Feb |
|
Impact of gemifloxacin on the normal human intestinal microflora. | 2001 Feb |
|
Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. | 2001 Feb |
|
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition. | 2001 Feb |
|
Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. | 2001 Feb |
|
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report. | 2001 Feb 15 |
|
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells. | 2001 Jan |
|
[In vitro antimycobacterial activities of a new quinolone, balofloxacin]. | 2001 Jan |
|
Community-acquired pneumonia. Diagnostic and therapeutic approach. | 2001 Jan |
|
In vitro and in vivo antimicrobial activity of topical ofloxacin and other ototopical agents. | 2001 Jan |
|
[Levofloxacin adverse effects, data from clinical trials and pharmacovigilance]. | 2001 Jan-Feb |
|
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams. | 2001 Jul |
|
New directions in antiinfective therapy for community-acquired pneumonia in the emergency department. | 2001 Jul |
|
The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia. | 2001 Jul |
|
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice. | 2001 Jul |
|
Activity of levofloxacin and ciprofloxacin against urinary pathogens. | 2001 Jul |
|
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae. | 2001 Jun |
|
Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy. | 2001 Jun |
|
Levofloxacin failure in a patient with pneumococcal pneumonia. | 2001 Jun |
|
Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae isolates from Crete, Greece. | 2001 Jun |
|
Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. | 2001 Jun |
|
Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages. | 2001 Mar |
|
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae. | 2001 Mar |
|
Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice. | 2001 Mar |
|
Treatment of tularemia with levofloxacin. | 2001 Mar |
|
A case of renal involvement in persistent immune activation caused by chlamydial salpingitis. | 2001 Mar |
|
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography. | 2001 Mar |
|
Adverse reactions to fluoroquinolones. an overview on mechanistic aspects. | 2001 Mar |
|
Clinical perspectives on new antimicrobials: focus on fluoroquinolones. | 2001 Mar 15 |
|
Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model. | 2001 Mar 15 |
|
In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany. | 2001 Mar-Apr |
|
Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery. | 2001 May |
|
Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones. | 2001 May |
|
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. | 2001 May |
|
An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum. | 2001 May |
|
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates. | 2001 May 15 |
|
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. | 2001 May-Jun |
|
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. | 2001 May-Jun |
|
In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens. | 2001 May-Jun |
Sample Use Guides
The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours.
Nosocomial Pneumonia: 750 mg during 7–14 days
Community Acquired Pneumonia: 500 mg during 7–14 days
Community Acquired Pneumonia§ 750 mg during 5 days
Complicated Skin and Skin Structure Infections (SSSI) 750 mg during 7–14 days
Uncomplicated SSSI 500 mg during 7–10 days
Chronic Bacterial Prostatitis 500 mg during 28 days
Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 750 mg during 5 days
Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 250 mg during 10 days
Uncomplicated Urinary Tract Infection 250 mg 3 during days
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg during 7 days
Acute Bacterial Sinusitis (ABS) 750 mg days or 500 mg during 10–14 days.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8077990
Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:00:08 UTC 2023
by
admin
on
Wed Jul 05 23:00:08 UTC 2023
|
Record UNII |
6GNT3Y5LMF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
S01AE05
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
WHO-ATC |
A02BD10
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
NDF-RT |
N0000007606
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
FDA ORPHAN DRUG |
253707
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
WHO-ATC |
J01MA12
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
LIVERTOX |
NBK548357
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
NDF-RT |
N0000175937
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/08/566
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
WHO-VATC |
QS01AE05
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
WHO-VATC |
QJ01RA05
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
WHO-ATC |
J01RA05
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
QUINSAIR (AUTHORIZED: CYSTIC FIBROSIS)
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
||
|
WHO-VATC |
QJ01MA12
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C1586
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
1362103
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
6GNT3Y5LMF
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
6GNT3Y5LMF
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
LEVOFLOXACIN
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
DTXSID60160533
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
1569
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
63598
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
II-30
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
SUB21640
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
138199-71-0
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
M8133
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
100000091529
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
3033924
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
Levofloxacin
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
DB01137
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | |||
|
82122
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL33
Created by
admin on Wed Jul 05 23:00:08 UTC 2023 , Edited by admin on Wed Jul 05 23:00:08 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
ROUTE OF ADMINISTRATION: ORAL AND INJECTION
BINDING
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MIC | PHARMACOKINETIC |
|
SUSCEPTIBILITY: RESISTANT |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
POPULATION: INFANTS ≥ 6 MONTHS, CHILDREN, AND ADOLESCENTS ≤ 16 YEARS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: CHILDREN 12-16 YEARS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: CHILDREN 5-10 YEARS |
|
||
Tmax | PHARMACOKINETIC |
|
|
|||
MIC | PHARMACOKINETIC |
|
SUSCEPTIBILITY: SUSCEPTIBLE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: ADULTS WITH RENAL IMPAIRMENT (CrCL < 20 ML/MIN) |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: CHILDREN 10-12 YEARS |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: ADULTS WITH RENAL IMPAIRMENT (CrCL 20-49 ML/MIN) |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
POPULATION: ADULTS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: INFANTS ≥ 6 MONTHS AND CHILDREN ≤ 5 YEARS |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: ADULTS |
|
||
MIC | PHARMACOKINETIC |
|
SUSCEPTIBILITY: INTERMEDIATE |
|
||